Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Bo Yoon Chang, In Soo Kim, Hyung‐Min Park, Sun‐Chang Kim, Sung Yeon KimNutrients 2025 · DOI

TL;DR

This study investigates SGB121, a novel extract enriched in ginsenoside F1 from Panax ginseng, as a potential treatment for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). SGB121 effectively reduced liver fat accumulation, oxidative stress, and improved insulin sensitivity in a mouse model of MAFLD, suggesting its promise as a multifunctional nutraceutical.

What Problem Does This Paper Address?

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a growing global health concern, characterized by excessive fat in the liver, insulin resistance, oxidative stress, and inflammation. Current pharmacological treatments are limited, necessitating the exploration of novel therapeutic strategies. Ginsenoside F1, a compound found in Panax ginseng, shows promise for metabolic health, but its difficult purification and high production costs have hindered its widespread use. This paper addresses this by developing SGB121, a standardized extract enriched in ginsenoside F1, and evaluating its efficacy and underlying mechanisms in combating MAFLD.

Methods

The researchers employed a two-pronged approach:

  • In Vivo Study: A high-fat, high-carbohydrate (HFHC) diet was used to induce MAFLD in male C57BL/6 mice. These mice were then treated with varying doses of SGB121 (50, 100, and 200 mg/kg) or metformin (a positive control). Standardized measurements included body weight, body composition (using DEXA), liver weight, hepatic lipid accumulation (via Oil Red O staining), oxidative stress markers (MDA and GSH), fasting blood glucose, insulin levels, and HOMA-IR. Lipid profiles (triglycerides and cholesterol) and liver function enzymes (ALT and AST) were also assessed.
  • In Vitro Study: Human hepatocellular carcinoma (HepG2) cells were used to model MAFLD. These cells were exposed to free fatty acids (FFAs) to induce steatosis and oxidative stress. The effects of SGB121 and purified ginsenoside F1 were then evaluated on cell viability, intracellular reactive oxygen species (ROS) levels, and lipid accumulation. Mechanistic studies focused on the activation of key signaling pathways, including AMPK, and the expression of proteins and genes involved in lipid metabolism, antioxidant defense, and insulin signaling.

Datasets

Not discussed in the paper. The study utilized established animal models and cell lines, along with standard laboratory reagents and assays.

Key Insights and Ideas

  • Standardization is Key: The development of SGB121, an enriched extract, overcomes the limitations of relying on oral administration of less purified ginseng components, which have variable absorption and efficacy due to individual gut microbiota differences.
  • Multi-Targeted Action: SGB121 doesn't just tackle one aspect of MAFLD; it simultaneously addresses lipid accumulation, oxidative stress, and insulin resistance, highlighting its potential as a comprehensive therapeutic agent.
  • AMPK as a Central Hub: The research strongly implicates the activation of AMPK by ginsenoside F1 as a core mechanism for regulating lipid metabolism, promoting fatty acid oxidation, and inhibiting de novo lipogenesis.
  • Synergistic Effects: While purified ginsenoside F1 showed significant effects, the study suggests that the therapeutic benefits of SGB121 may arise from synergistic interactions among multiple ginsenosides present in the extract, not just F1 alone.

Key Results

  • In Vivo: SGB121 treatment significantly reduced body weight gain and fat accumulation in MAFLD mice, with the most pronounced effects seen at 200 mg/kg. It also attenuated hepatic lipid accumulation, reduced oxidative stress markers (MDA), and restored glutathione (GSH) levels. Furthermore, SGB121 significantly improved glucose homeostasis and insulin sensitivity, as evidenced by reduced fasting glucose, insulin, and HOMA-IR, comparable to metformin.
  • In Vitro: SGB121 and ginsenoside F1 effectively reduced FFA-induced ROS generation and lipid accumulation in HepG2 cells. Mechanistically, F1 activated AMPK, upregulated PPARα and CPT1 (involved in fatty acid oxidation), downregulated SREBP1c, ACC, and FAS (involved in lipogenesis), and restored IRS/Akt/GLUT2 signaling, promoting glucose uptake.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Animal Model: The study primarily used one animal model (HFHC diet-induced MAFLD in C57BL/6J mice) and a single dosing regimen.
  • Surrogate Biomarkers: Mechanistic analyses relied heavily on surrogate biomarkers.
  • Future Directions: The authors suggest future research should encompass:
  • Studies with different metabolic phenotypes and sex-based variations.
  • Investigations into gut-liver axis interactions.
  • Comprehensive pharmacokinetic and safety evaluations.
  • Clinical trials to establish the applicability of SGB121 for MAFLD management.

Summary updated

Abstract

<b>Introduction/Objectives</b>: Ginsenoside F1, a pharmacologically active saponin derived from Panax ginseng, exhibits diverse bioactivities, but its use is limited because it is difficult to purify and has high production costs. To overcome these challenges, a ginsenoside F1-enriched extract named SGB121 was developed. This study aimed to evaluate the therapeutic efficacy of SGB121 in a high-fat, high-carbohydrate (HFHC) diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mouse model and to elucidate its mechanism of action using F1-based cellular assays. <b>Methods</b>: Male C57BL/6 mice (6 weeks old) were fed an HFHC diet to induce MAFLD and were treated with SGB121. Hepatic lipid accumulation, oxidative stress markers, and metabolic parameters were analyzed. In parallel, human hepatocellular carcinoma (HepG2) cells exposed to free fatty acids (FFAs) were used to assess oxidative stress and lipid accumulation. Mechanistic studies were conducted using purified F1 to examine adenosine monophosphate-activated protein kinase (AMPK) activation and related pathways. <b>Results</b>: SGB121 reduced hepatic lipid accumulation, malondialdehyde (MDA) levels, and fasting insulin while restoring glutathione (GSH) content and improving the homeostasis model assessment of insulin resistance (HOMA-IR) in MAFLD mice. In FFA-treated HepG2 cells, both SGB121 and F1 decreased reactive oxygen species (ROS), suppressed sterol regulatory element-binding protein 1 (SREBP1), enhanced peroxisome proliferator-activated receptor-α (PPARα) and β-oxidation, and restored insulin receptor substrate (IRS)/protein kinase B (Akt)/glucose transporter 2 (GLUT2) signaling. <b>Conclusions</b>: SGB121 ameliorates MAFLD and related metabolic dysfunction through antioxidant, lipid-regulating, and insulin-sensitizing actions, highlighting its potential as a safe multifunctional nutraceutical for MAFLD management.
BibTeX
@inproceedings{chang2025protective,
  author = {Bo Yoon Chang and In Soo Kim and Hyung‐Min Park and Sun‐Chang Kim and Sung Yeon Kim and Sung Yeon Kim and Sung Yeon Kim},
  title = {{Protective Role of Ginsenoside F1-Enriched Extract (SGB121) in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)}},
  booktitle = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17233693},
}
Figure